Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial

被引：8

作者：

Conte, Benedetta ^{[1
,2
]}

Bruzzone, Marco ^{[3
]}

Lambertini, Matteo ^{[4
,5
]}

Poggio, Francesca ^{[1
]}

Bighin, Claudia ^{[1
]}

Blondeaux, Eva ^{[1
]}

De Laurentiis, Michelino ^{[6
]}

Valle, Enrichetta ^{[7
]}

Cognetti, Francesco ^{[8
]}

Nistico, Cecilia ^{[9
]}

De Placido, Sabino ^{[10
]}

Garrone, Ornella ^{[11
]}

Gamucci, Teresa ^{[12
,13
]}

Montemurro, Filippo ^{[14
]}

Puglisi, Fabio ^{[15
,16
]}

Cardinali, Barbara ^{[17
]}

Fregatti, Piero ^{[18
,19
]}

Miglietta, Loredana ^{[1
]}

Boccardo, Francesco ^{[4
]}

Ceppi, Marcello ^{[3
]}

Del Mastro, Lucia ^{[17
]}

机构：

[1] IRCCS Osped Policlin San Martino, Med Oncol Unit 2, Largo Rosanna Benzi 10, I-16132 Genoa, GE, Italy

[2] August Pi & Sunyer Biomed Res Inst, Translat Genom & Targeted Therapeut Solid Tumors, Carrer Rossello 149, Barcelona 08036, Spain

[3] IRCCS Osped Policlin San Martino, Clin Epidemiol Unit, Largo Rosanna Benzi 10, I-16132 Genoa, GE, Italy

[4] IRCCS Osped Policlin San Martino, UOC Clin Oncol Med, Dept Med Oncol, Largo Rosanna Benzi 10, I-1632 Genoa, GE, Italy

[5] Univ Genoa, Sch Med, Dept Internal Med & Med Specialties DiMI, Viale Benedetto XV 10, I-16132 Genoa, GE, Italy

[6] Ist Nazl Tumori Fdn G Pascale, Breast Unit, Via Mariano Semmola 53, I-80131 Naples, NA, Italy

[7] Osped Businco, Dept Med Oncol, Via Edward Jenner 1, I-09121 Cagliari, CA, Italy

[8] Univ Roma La Sapienza, Dept Clin & Mol Med, Viale Regina Elena 324, I-00161 Rome, RM, Italy

[9] Ist Nazl Tumori Regina Elena, Dept Med Oncol 1, Via Elio Chianesi 53, I-00128 Rome, RM, Italy

[10] Univ Naples Federico II, Dept Clin Med & Surg, Via Sergio Pansini 5, I-80131 Naples, NA, Italy

[11] Azienda Osped Santa Croce & Carle, Dept Oncol, Breast Unit, Via Michele Coppino 26, I-12100 Cuneo, CN, Italy

[12] Osped Sandro Pertini, Dept Med Oncol, Via Monti Tiburtini 385-389, I-00157 Rome, RM, Italy

[13] Osped SS Trinita, Dept Med Oncol, I-03039 Sora, FR, Italy

[14] FPO IRCCS, Candiolo Canc Inst, Multidisciplinary Oncol Outpatient Clin, Str Prov 42, I-10060 Turin, TO, Italy

[15] Univ Udine, Dept Med, Piazzale Massimiliano Kolbe 4, I-33100 Udine, Italy

[16] Natl Canc Inst, Dept Med Oncol, IRCCS Ctr Riferimento Oncol Aviano, Via Franco Gallini 2, I-33081 Aviano, PN, Italy

[17] IRCCS Osped Policlin San Martino, Breast Unit, Largo Rosanna Benzi 10, I-16132 Genoa, GE, Italy

[18] Univ Genoa, Dept Surg Sci & Integrated Diagnost DISC, Viale Benedetto XV 6, I-1612 Genoa, GE, Italy

[19] IRCCS Policlin San Martino, Dept Surg, Largo Rosanna Benzi 10, I-1632 Genoa, GE, Italy

来源：

EUROPEAN JOURNAL OF CANCER | 2020年 / 136卷

关键词：

Breast cancer; Dose-dense chemotherapy; Hormone receptor-positive; Luminal subtype; INTERNATIONAL EXPERT CONSENSUS; PHASE-III; PLUS CYCLOPHOSPHAMIDE; PRIMARY THERAPY; WOMEN; DOCETAXEL; SURVIVAL; BENEFIT; KI67; RECURRENCE;

D O I：

10.1016/j.ejca.2020.05.007

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Luminal A-like and luminal B-like subtypes have different sensitivity to (neo)adjuvant chemotherapy, but their role in predicting dose-dense (DD) efficacy in the high-risk setting is unknown. In this exploratory analysis of the Gruppo Italiano Mammella 2 (GIM2) trial, we investigated DD efficacy according to luminal-like subtypes. Methods: Patients with node-positive early breast cancer were randomised to receive either DD or standard-interval (SI) anthracycline-based chemotherapy followed by paclitaxel. In our analysis, luminal A-like cohort was identified as having a Ki67 < 20% and a progesterone receptor (PgR) >= 20%; luminal B-like cohort as having a Ki67 >= 20% and/or a PgR < 20%. Results: Out of 2003 patients enrolled in the GIM2 trial, 412 had luminal A-like and 638 luminal B-like breast cancer. After a median follow-up of 7.9 years, disease-free survival (DFS) was 80.8% (95% confidence interval [CI] 76.4-84.5) and 70.5% (66.5-74.2) in luminal A-like and luminal B-like cohorts; overall survival (OS) was 91.6% (88.2-94.1) and 85.1% (81.7-87.9), respectively. We found no significant interaction between treatment and luminal subtype (interaction p = 0.603 and 0.535 for DFS and OS, respectively). When DD efficacy was investigated separately in each cohort, luminal-B like cohort appeared to benefit more from the DD schedule both in terms of DFS (unadjusted hazard ratio [HR] 0.72 [95% CI 0.54-0.96]) and OS (unadjusted HR 0.61 [95% CI 0.40-0.94]), compared with the luminal A-like cohort (unadjusted HR for DFS 0.89 [95% CI 0.59-1.33]; unadjusted HR for OS 0.83 [95% CI 0.45-1.54]). Conclusions: No significant interaction between luminal-like subtype and treatment was observed. Patients in the luminal B-like cohort seemed to benefit more from DD schedule. (C) 2020 Elsevier Ltd. All rights reserved.

引用

页码：43 / 51

页数：9

共 50 条

[31] Adjuvant Chemotherapy Decisions in Clinical Practice for Early-Stage Node-Negative, Estrogen Receptor-Positive, HER2-Negative Breast Cancer: Challenges and Considerations
Nagaraj, Gayathri
Ma, Cynthia X.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (03): : 246 - 251
[32] Race and clinical outcomes in hormone receptor-positive, HER2-negative, node-positive breast cancer in the randomized RxPONDER trial
Abdou, Yara
Barlow, William E.
Gralow, Julie R.
Meric-Bernstam, Funda
Albain, Kathy S.
Hayes, Daniel F.
Lin, Nancy U.
Perez, Edith A.
Goldstein, Lori J.
Chia, Stephen K. L.
Dhesy-Thind, Sukhbinder
Rastogi, Priya
Alba, Emilio
Delaloge, Suzette
Schott, Anne F.
Shak, Steven
Sharma, Priyanka
Lew, Danika L.
Miao, Jieling
Unger, Joseph M.
Tripathy, Debasish
Hortobagyi, Gabriel N.
Pusztai, Lajos
Kalinsky, Kevin
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2025,
[33] What Is the Optimal Model to Estimate the Benefits of Chemotherapy in Patients With Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer?
Ando, Kenju
Shimomura, Akihiko
Yoshimura, Kenichi
Kawamura, Yukino
Shimizu, Chikako
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (17) : 1946 - +
[34] Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2-negative breast cancer
Kearney, Matthew R.
McGuinness, Julia E.
Kalinsky, Kevin
BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (01) : 1 - 13
[35] A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer
Harbeck, Nadia
Burstein, Harold J.
Hurvitz, Sara A.
Johnston, Stephen
Vidal, Gregory A.
CANCER, 2022, 128 : 2209 - 2223
[36] Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial
Lambertini, Matteo
Campbell, Christine
Gelber, Richard D.
Viale, Giuseppe
McCullough, Ann
Hilbers, Florentine
Korde, Larissa A.
Werner, Olena
Chumsri, Saranya
Jackisch, Christian
Wolff, Antonio C.
Vaz-Luis, Ines
Ferreira, Arlindo R.
Prat, Aleix
Moreno-Aspitia, Alvaro
Piccart, Martine
Loi, Sherene
de Azambuja, Evandro
BREAST CANCER RESEARCH AND TREATMENT, 2019, 177 (01) : 103 - 114
[37] Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
Gabe S. Sonke
Lowell L. Hart
Mario Campone
Frans Erdkamp
Wolfgang Janni
Sunil Verma
Cristian Villanueva
Erik Jakobsen
Emilio Alba
Erik Wist
Anne M. Favret
Thomas Bachelot
Roberto Hegg
Paul Wheatley-Price
Farida Souami
Santosh Sutradhar
Michelle Miller
Caroline Germa
Howard A. Burris
Breast Cancer Research and Treatment, 2018, 167 : 659 - 669
[38] Palbociclib and letrozole for hormone receptor-positive HER2-negative breast cancer with residual disease after neoadjuvant chemotherapy
Pernas, Sonia
Sanfeliu, Esther
Villacampa, Guillermo
Salvador, Javier
Perello, Antonia
Gonzalez, Xavier
Jimenez, Begona
Merino, Maria
Palacios, Patricia
Pascual, Tomas
Alba, Emilio
Villanueva, Lorea
Chillara, Samyukta
Ferrero-Cafiero, Juan Manuel
Galvan, Patricia
Prat, Aleix
Ciruelos, Eva
NPJ BREAST CANCER, 2024, 10 (01)
[39] New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients
Yamamura, Jun
Kamigaki, Shunji
Fujita, Junya
Osato, Hiroki
Manabe, Hironobu
Tanaka, Yumiko
Shinzaki, Wataru
Hashimoto, Yukihiko
Komoike, Yoshifumi
BMC CANCER, 2021, 21 (01)
[40] New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients
Jun Yamamura
Shunji Kamigaki
Junya Fujita
Hiroki Osato
Hironobu Manabe
Yumiko Tanaka
Wataru Shinzaki
Yukihiko Hashimoto
Yoshifumi Komoike
BMC Cancer, 21

← 1 2 3 4 5 →